Plain-English translation of NCT06463522 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach called autologous tumor-infiltrating lymphocytes therapy for patients with hepatocellular carcinoma (liver cancer). Doctors will take immune cells from your tumor, grow many more of them in the laboratory, and then give them back to you through an infusion. The goal is to see whether this treatment is safe and whether it helps your body fight the cancer.
Standard treatments for advanced liver cancer have limited effectiveness, and doctors are looking for new ways to help patients. This treatment harnesses your own immune system to recognize and attack cancer cells, which is a promising approach that hasn't been thoroughly tested in liver cancer yet.
First, doctors will remove some of your tumor tissue to collect immune cells. Those cells will then be sent to a laboratory where they will be grown and multiplied over several weeks. Once ready, you will receive a single intravenous infusion of these cells at the hospital. You will need to stay at the enrollment center for treatment and follow-up visits to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Beijing 302 Hospital
Enrollment target
~20 participants
Started
July 2024
Primary completion
July 2025
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Junliang Fu, PhD, MD
the Fifth Medical Center of PLA